Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Cancer Research|August 29, 2014
β-catenin contributes to lung tumor development induced by EGFR mutationsSohei Nakayama, Natasha Sng, Julian Carretero, et al.
Cancer Science|March 14, 2023
TIP60 is required for tumorigenesis in non-small cell lung cancerDaisuke Shibahara, Naoki Akanuma, Ikei S Kobayashi, et al.
JCO Precision Oncology|June 21, 2021
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerJoel W Neal, Daniel B Costa, Alona Muzikansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerLecia V Sequist, Joachim von Pawel, Edward G Garmey, et al.
Clinical Lung Cancer|July 13, 2020
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung CancerKartik Sehgal, Anushi Bulumulle, Heather Brody, et al.
Molecular Cancer Research : MCR|August 31, 2019
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> MutationsHibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.
Clinical Lung Cancer|April 30, 2015
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic ProfilingXiuning Le, Jason A Freed, Paul A VanderLaan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 21, 2012
Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencingDaniela S Basseres, Francesco D'Alò, Beow Y Yeap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Identification of a RAS-activating <i>TMEM87A-RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung CancerAlissa J Cooper, Yoshihisa Kobayashi, Dewey Kim, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Cancer Research|August 29, 2014
β-catenin contributes to lung tumor development induced by EGFR mutationsSohei Nakayama, Natasha Sng, Julian Carretero, et al.
Cancer Science|March 14, 2023
TIP60 is required for tumorigenesis in non-small cell lung cancerDaisuke Shibahara, Naoki Akanuma, Ikei S Kobayashi, et al.
JCO Precision Oncology|June 21, 2021
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerJoel W Neal, Daniel B Costa, Alona Muzikansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerLecia V Sequist, Joachim von Pawel, Edward G Garmey, et al.
Clinical Lung Cancer|July 13, 2020
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung CancerKartik Sehgal, Anushi Bulumulle, Heather Brody, et al.
Molecular Cancer Research : MCR|August 31, 2019
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> MutationsHibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.
Clinical Lung Cancer|April 30, 2015
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic ProfilingXiuning Le, Jason A Freed, Paul A VanderLaan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 21, 2012
Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencingDaniela S Basseres, Francesco D'Alò, Beow Y Yeap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Identification of a RAS-activating <i>TMEM87A-RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung CancerAlissa J Cooper, Yoshihisa Kobayashi, Dewey Kim, et al.
Pageof 18